Michael Green - Fulcrum Therapeutics Co-Founder
| FULC Stock | USD 3.96 0.07 1.74% |
Founder
Mr. Michael R. Green, M.D., Ph.D., is a CoFounder of the Company. Green received his M.D. and Ph.D. from Washington University School of Medicine in 1981. He carried out postdoctoral work at Harvard University, where he joined as a faculty member in 1984. In 1990, he joined the Program in Molecular Medicine at the University of Massachusetts Medical School, and served as the director of the Program of Gene Function and Expression from 1999 to 2014. He has made pioneering contributions to the understanding of the mechanisms that regulate gene expression in eukaryotes and how alterations in gene expression contribute to cancer and other human diseases. Recently he has used transcriptionbased approaches and functional screens to identify new genes and regulatory pathways involved in epigenetic regulation and cancer, which have important therapeutic implications. As a young investigator he was the recipient of the Presidential Young Investigators Award, the Searle Scholar Award, the McKnight Neuroscience Award and was a Harvey Lecturer . He is an elected member of the National Academy of Sciences, National Academy of Medicine and the European Molecular Biology Organization .
| Address | 26 Landsdowne Street, Cambridge, MA, United States, 02139 |
| Phone | 617 651 8851 |
| Web | https://www.fulcrumtx.com |
Fulcrum Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0689) % which means that it has lost $0.0689 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0737) %, meaning that it created substantial loss on money invested by shareholders. Fulcrum Therapeutics' management efficiency ratios could be used to measure how well Fulcrum Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 15, 2024, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.48. At present, Fulcrum Therapeutics' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 3.9 M, whereas Total Assets are forecasted to decline to about 164.9 M.Management Performance
| Return On Equity | -0.0737 | ||||
| Return On Asset | -0.0689 |
Fulcrum Therapeutics Leadership Team
Elected by the shareholders, the Fulcrum Therapeutics' board of directors comprises two types of representatives: Fulcrum Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fulcrum. The board's role is to monitor Fulcrum Therapeutics' management team and ensure that shareholders' interests are well served. Fulcrum Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fulcrum Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Green, Co-Founder | ||
| Rudolf MD, Founder | ||
| CPA CMA, Chief Officer | ||
| Jeffrey Jacobs, Chief Officer | ||
| Mel Hayes, Executive Experience | ||
| Paul Bruno, Senior Development | ||
| Bryan Stuart, CEO Pres | ||
| Alexander Sapir, President CEO | ||
| Esther Rajavelu, CFO Treasurer | ||
| Gregory Tourangeau, Controller Officer | ||
| Prof MD, Founder | ||
| Danny Reinberg, Founder | ||
| TsunHuei MD, Founder | ||
| Curtis JD, Chief VP | ||
| Judith Dunn, Interim Officer |
Fulcrum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fulcrum Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0737 | ||||
| Return On Asset | -0.0689 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | 0.66 % | ||||
| Current Valuation | (34.49 M) | ||||
| Shares Outstanding | 53.94 M | ||||
| Shares Owned By Insiders | 1.62 % | ||||
| Shares Owned By Institutions | 89.69 % | ||||
| Number Of Shares Shorted | 4.58 M | ||||
| Price To Earning | (1.99) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 1.317 | Quarterly Revenue Growth 89.909 | Return On Assets (0.07) | Return On Equity (0.07) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.